Here, we report, (i) the generation of highly specific, fully human scFv sequences from a naïve human B cell library against FOLR1, (ii) the functional high-throughput in vitro assessment of anti-FOLR1 CAR T cells based on these fully human scFv sequences, and (iii) the tissue cross-reactivity characterization of the anti-FOLR1 scFvs to assess off-target and on-target/off-tumor binding. This evidence concerns the gene FOLR1 and neoplasm.